GlassScriptPhysician profile
Shital R Patel
NPI 1942214572
$35,281.74
in general payments reported to CMS, 2019-2025
60 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,633 · 2021: $3,168 · 2022: $2,999 · 2023: $3,086 · 2024: $2,587 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,538 · Consulting Fee: $4,500 · Travel and Lodging: $1,783 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $350 · Education: $74.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,537.61 |
| Consulting Fee | $4,500.00 |
| Travel and Lodging | $1,783.03 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $350.00 |
| Education | $74.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,383.49 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Valeritas, INC. | $5,585.34 | 2019 | |
| Lilly USA, LLC | $2,382.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $2,220.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $2,069.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,931.22 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $1,707.74 | 2019-2025 | Evenity, Prolia, Repatha |
| Mannkind Corporation | $1,149.24 | 2019-2025 | Afrezza |
| Tosoh Bioscience, INC. | $1,078.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $979.02 | 2019-2022 | |
| Abbvie INC. | $654.33 | 2019-2025 | |
| Dexcom, INC. | $528.14 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amneal Pharmaceuticals LLC | $514.75 | 2019-2025 | Unithroid |
| Radius Health, INC. | $511.81 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $467.30 | 2019-2021 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $466.72 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $411.95 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Beta Bionics, INC. | $325.62 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Horizon Therapeutics Plc | $287.16 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $243.91 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $228.82 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $217.98 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.87 | 2019-2023 | Cycloset |
| Antares Pharma, INC. | $189.77 | 2019-2025 | Xyosted |
| Zealand Pharma US, INC. | $187.14 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $154.86 | 2019-2020 | |
| Sequel Med Tech, LLC | $143.25 | 2025 | Twiist |
| Corcept Therapeutics | $142.51 | 2021-2025 | Korlym |
| Recordati_rare_diseases_inc. | $142.38 | 2021-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $131.18 | 2021-2023 | Omnipod |
| Pfizer INC. | $126.80 | 2019-2025 | |
| Lifescan, INC. | $109.15 | 2019-2022 | |
| Cequr Corporation | $107.47 | 2021-2025 | Cequr Simplicity |
| Vivus LLC | $104.56 | 2019-2024 | Qsymia |
| Shire North American Group INC | $102.28 | 2019 | |
| Ascendis Pharma Endocrinology INC | $96.23 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $95.43 | 2025 | Rezdiffra |
| Endo Pharmaceuticals INC. | $94.76 | 2020-2021 | |
| Alvogen INC | $88.93 | 2025 | Teriparatide |
| Ibsa Pharma INC. | $78.73 | 2020-2025 | Licart, Flector, Tirosint |
| Kyowa Kirin, INC. | $67.79 | 2023-2024 | Crysvita |
| Medtronic, INC. | $65.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $59.40 | 2019-2020 | |
| Nevro Corp. | $54.03 | 2022-2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $34.34 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $32.78 | 2020 | |
| Quidel Corporation | $32.32 | 2019 | |
| Acella Pharmaceuticals, LLC | $32.17 | 2024-2025 | NP Thyroid 60 |
| Boston Scientific Corporation | $31.40 | 2025 | General - Pain Management |
| Alfasigma USA, INC. | $30.56 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $28.60 | 2025 | Tlando |
| Avvisto Therapeutics, LLC | $20.99 | 2025 | Cycloset |
| Globus Medical, INC. | $19.72 | 2025 | Senza |
| Azurity Pharmaceuticals, INC. | $18.90 | 2023 | Adthyza |
| Halozyme INC | $18.03 | 2023 | |
| Esperion Therapeutics, INC. | $17.83 | 2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $17.61 | 2020 | |
| Currax Pharmaceuticals LLC | $16.67 | 2021 | |
| Tolmar, INC. | $13.38 | 2023 | |
| Cardiovascular Systems INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shital Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.